PPT-Chapter 26 Drug Therapy for Hypertension

Hypertension Overview Common chronic disorder affecting more than 100 million adults in the United States Hypertension the risk of MI HF Cerebral infarction and hemorrhage Renal disease. Drugs for Multiple Sclerosis. Multiple Sclerosis (MS). Chronic, inflammatory, autoimmune disorder that damages the myelin sheath of neurons in the CNS. Exact cause is unknown. MS causes a wide variety of sensory and motor deficits. Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder. CNS Stimulants. Increase the activity of CNS neurons. Enhance neuronal excitation; a few suppress neuronal inhibition. In sufficient doses, all can cause convulsions. GUEST EXPERT:. John M. Flack M.D, M.P.H., F.A.H.A., F.A.C.P., F.A.S.H.. Professor and Chair. Chief, Hypertension Section (GIM). Department of Medicine. Southern Illinois University. Vice President, ASH Specialist Board. Geriatric Patients. Disproportionately high prescription drug use exists in the elderly.. 12% of Americans are age 65 years or older.. This 12% consumes 31% of prescribed drugs.. Geriatric patients experience more adverse drug reactions and drug-drug interactions than younger patients do.. The More We Learn, the Less We Know. Zeb K. . Henson, . M.D.. Assistant Professor, Department of Medicine . & Department . of Pediatrics. University of Mississippi Medical Center. Financial Disclosures. ACCF/AHA 2011. Expert Consensus Document. . . Developed in collaboration with the American Academy of Neurology, Association of Black Cardiologists, American Geriatrics Society, American Society of Hypertension, American Society of Nephrology, American Society for Preventive Cardiology, and the European Society of Hypertension. PGY-2 Oncology Pharmacy Resident. Pharmacy Grand Rounds. September 6th, 2016. Giving the TKO to . Metabolic Adverse Effects . of the TKIs. Objectives. List common tyrosine kinase inhibitors known to cause metabolic adverse effects (e.g. cardiac, hypothyroidism, hypo/hyperglycemia) . MARLON T. CO,MD. DISCLOSURE. Advisory board of Merck Philippines. Ps-DZ, 2009. Global Leading Risks for Death, 2010. Systolic blood pressure > 115 mmHg. Global Burden of Disease Study 2010 , . Lancet . PGYV PULMONARY FELLOW. FINANCIAL DISCLOSURES. None. OBJECTIVES. Learn to define the disorder. Classification and prevalence. Pathophysiology and histopathology. Presentation. Screening and diagnostic methods. . Fuad. بورد عراقي (دكتوراه) في الطب الباطني. بورد عربي (دكتوراه) في الطب الباطني. بورد عراقي (دكتوراه). . تخصص دقيق في أمراض وقسطرة القلب والشرايين. 2013 ESH-ESC Guidelines for the Management of Arterial Hypertension . 2013 ESH/ESC Hypertension Guidelines. Journal of Hypertension 2013. European Heart Journal 2013. Blood Pressure 2013. Levels of evidence. A Public Health Role for Minnesota Pharmacists. James Peacock, PhD, MPH. PROTECTING, MAINTAINING AND IMPROVING THE HEALTH OF ALL MINNESOTANS. Cardiovascular Disease & Diabetes in Minnesota. Heart Disease (2. . Aqeel. Shams. M.B.Ch.B. /MSc. Clinical pharmacology. . Hypertension . is defined as a sustained systolic blood pressure of 140 mm Hg or higher or a sustained diastolic blood pressure of 90 mm Hg or higher. . and. Pregnancy Treatment Trial. Alan T.N. Tita, MD, PhD. University of Alabama at Birmingham Heersink School of . Medicine . for the CHAP . Consortium. Society for Clinical Trials 2023: Trial of the Year Session.